19 Oct 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Shanghai Fosun Pharmaceutical is going to list its shares on the main board of Stock Exchange of Hong Kong Limited (SEHK). The Hong Kong public offering opened at 9:00 am on October 17, 2012, Wednesday, and close at 12:00 noon on October 22, 2012, Monday. Dealings of shares on the SEHK are expected to commence on October 30, 2012, Tuesday, under the stock code 02196 in board lots of 500 shares each.
The company plans to offer an aggregate of 336,070,000 H Shares, of which approximately 302,463,000 H shares are international offer shares (subject to adjustment and the over allotment option) and approximately 33,607,000 H shares are Hong Kong offer shares (subject to adjustment).
The joint global coordinators, joint sponsors, joint bookrunners and joint lead managers of this finiancial event include, UBS AG, Hong Kong; China International Capital Corporation; JP Morgan Securities and Deutsche Bank, Hong Kong.
Besides SSE 180 Index, CSI 300 Index, SSE Dividend Index, and SSE Corporate Governance Index, Fosun Pharma has also been successfully included in the SSE Private Enterprise 50 Index and SSE Social Responsibility Index. It is forecast that basic earnings per share for 2012 would be $0.1072 (RMB0.67 or HK$0.81) (not taking into account any H Shares that may be issued pursuant to exercise of the over-allotment option).
Mr Chen Qiyu, executive director and chairman, Fosun Pharma, said that, "Currently, around 80 percent of our revenue generated by pharmaceutical businesses is contributed by the China market. We believe this position will continue in the future for a relatively long period."